{
    "clinical_study": {
        "@rank": "99157", 
        "arm_group": [
            {
                "arm_group_label": "Fixed-dose combination VR 160/20 mg-1", 
                "arm_group_type": "Experimental", 
                "description": "Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15."
            }, 
            {
                "arm_group_label": "Fixed-dose combination VR 160/20 mg-2", 
                "arm_group_type": "Experimental", 
                "description": "Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15."
            }, 
            {
                "arm_group_label": "Valsartan 160mg placebo + Rosuvastatin 20mg", 
                "arm_group_type": "Experimental", 
                "description": "Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the safety and pharmacokinetics between ROVATITAN tab. 160/20 mg (ROVATITAN tab\n      160/20mg-1, ROVATITAN tab. 160/20mg-2)  and coadministration of Diovan\u00ae (Valsartan) 160 mg\n      and Crestor\u00ae (Rosuvastatin) 20 mg in healthy male volunteers"
        }, 
        "brief_title": "Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan\u00ae (Valsartan) Film-coated Tablet 160 mg and Crestor\u00ae (Rosuvastatin) 20 mg", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypertension", 
            "Hyperlipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male aged 20~45 years at screening\n\n          2. 19 kg/m2 \u2264 BMI \u226427 kg/m2 at screening\n\n          3. Subject who is able to communicate with investigators and understand the nature of\n             the clinical study and is willing and able to provide a written informed consent form\n\n        Exclusion Criteria:\n\n          1. Subject with current or previous clinically significant diseases in liver, renal,\n             neurologic, pulmonary, gastrointestinal, endocrine, hematologic, oncologic,\n             cardiovascular,  psychological, and musculoskeletal system\n\n          2. Patient with renal defects (Calculated GFR < 60 ml/min based on serum creatinine\n             level )\n\n          3. Subject who can not satisfy the following criteria for sitting blood pressure at\n             screening test 90 \u2264SBP <140  (mmHg) 60 \u2264 DBP <90  (mmHg)\n\n          4. Subject who can not satisfy the following criteria at screening 1) AST and ALT \u2264 1.5x\n             ULN 2) Serum total bilirubin \u2264 1.5x ULN 3) CK (Creatinine kinase) \u2264 2x ULN\n\n          5. Subject with a medical history of gastrointestinal diseases (e.g., Crohn's disease,\n             ulcer) or a surgery (for appendicitis and hernia repair are allowed) that might\n             affect the investigational product absorption\n\n          6. Subject with hypersensitivity to the drugs containing components of valsartan and\n             rosuvastatin or other drugs (aspirin, antibiotics) or a previous clinically\n             significant history of hypersensitivity\n\n          7. Subject with a previous history of drug overdose or a positive to the drugs\n             (Barbiturate, Benzodiazepine, Methamphetamine, Cannabinoids, Cocaine, Opiate) in\n             urine drug screening test\n\n          8. Subject who has taken any prescribed medicines or oriental medicines within two weeks\n             before the first  investigational product administration, or who has taken any\n             over-the-counter drugs within one week before the first investigational product\n             administration (If the subject is eligible for all other criteria, he or she may\n             participate in the clinical study based on investigator's discretion.)\n\n          9. Subject who has taken other investigational products within 60 days before the first\n             investigational product administration\n\n         10. Subject who donated whole blood within 60 days or donated apheresis blood within 30\n             days or received a transfusion within 30 days before the first investigational\n             product administaration.\n\n         11. Subject who has taken the drugs that induce or inhibit drug-metabolizing enzymes such\n             as barbiturates within 30 days before the first investigational product\n             administration\n\n         12. Subject with a daily intake of drinks containing caffeine (coffee, tea, coke) or\n             grapefruit juice > average of 4 cups / day (800 mL) or a subject who can not\n             discontinue such drinks during the clinical study period(from screening to post-study\n             visit)\n\n         13. Subject with a mean weekly drinking amount of > 140g or a subject who can not stop\n             drinking until outpatient visit after the investigational product administration,\n             including the hospitalization in each period.\n\n         14. Subject with a mean daily smoking amount of > 10 cigarettes  or a subject who can not\n             stop smoking during the hospitalization\n\n         15. Subject positive result in serology tests  (hepatitis B, hepatitis C, HIV)\n\n         16. Subject with genetic muscle disease, or familial history of muscle disease, or\n             medical history of drug-derived muscle disorder\n\n         17. Subject who is considered not to be eligible at investigator's discretion."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918358", 
            "org_study_id": "LG-VRCL005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Fixed-dose combination VR 160/20 mg-1", 
                    "Fixed-dose combination VR 160/20 mg-2", 
                    "Valsartan 160mg placebo + Rosuvastatin 20mg"
                ], 
                "intervention_name": "Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rovatitan tab", 
                    "Diovan", 
                    "Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Fixed-dose combination VR 160/20 mg-1", 
                    "Fixed-dose combination VR 160/20 mg-2", 
                    "Valsartan 160mg placebo + Rosuvastatin 20mg"
                ], 
                "intervention_name": "Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rovatitan tab", 
                    "Diovan", 
                    "Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Fixed-dose combination VR 160/20 mg-1", 
                    "Fixed-dose combination VR 160/20 mg-2", 
                    "Valsartan 160mg placebo + Rosuvastatin 20mg"
                ], 
                "intervention_name": "Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rovatitan tab", 
                    "Diovan", 
                    "Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Fixed-dose combination VR 160/20 mg-1", 
                    "Fixed-dose combination VR 160/20 mg-2", 
                    "Valsartan 160mg placebo + Rosuvastatin 20mg"
                ], 
                "intervention_name": "Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rovatitan tab", 
                    "Diovan", 
                    "Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Fixed-dose combination VR 160/20 mg-1", 
                    "Fixed-dose combination VR 160/20 mg-2", 
                    "Valsartan 160mg placebo + Rosuvastatin 20mg"
                ], 
                "intervention_name": "Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rovatitan tab", 
                    "Diovan", 
                    "Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Fixed-dose combination VR 160/20 mg-1", 
                    "Fixed-dose combination VR 160/20 mg-2", 
                    "Valsartan 160mg placebo + Rosuvastatin 20mg"
                ], 
                "intervention_name": "Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rovatitan tab", 
                    "Diovan", 
                    "Crestor"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valsartan", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-label, Single Dose Crossover Study to Compare the Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan\u00ae (Valsartan) Film-coated Tablet 160 mg and Crestor\u00ae (Rosuvastatin) 20 mg in Healthy Male Volunteers", 
        "other_outcome": {
            "description": "The severity of adverse events and their relationship with the investigational products are schematized by treatment group. Descriptive statistics are calculated for the frequency, percentage, 12-lead ECG and clinical laboratory tests results of the subjects who have adverse events and the results of each item are reviewed.", 
            "measure": "Safety evaluation", 
            "safety_issue": "No", 
            "time_frame": "-28~-2d, 1d, 2d, 3d, 8d, 9d, 10d, 15d, 16d, 17d, 21 \u00b1 2d"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax of valsartan and rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 12h, 24h, 48h for each period (total 16 times)"
            }, 
            {
                "measure": "AUC last of valsartan and rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 12h, 24h, 48h for each period (total 16 times)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}